绝经后激素受体阳性HER2阴性早期乳腺癌患者体重指数与LORELEI试验探索性分析
LORELEI试验的探索性分析评估了绝经后雌激素受体阳性/HER2阴性早期乳腺癌患者中体重指数(BMI)与新辅助PI3K抑制剂taselisib联合来曲唑疗效和安全性的关联。结果显示,安慰剂组中较高BMI与较低的客观缓解率(ORR)相关(OR 0.90, 95%CI 0.83-0.97),而taselisib组无此关联(OR 1.03, 95%CI 0.96-1.11),交互作用P=0.007(未校正)。肥胖患者中高血糖和腹泻发生率分别为15.1%和24.5%。
要点
- 安慰剂组中较高BMI与较低ORR相关,taselisib组无此关联。
- 肥胖患者中高血糖发生率为15.1%,腹泻为24.5%。
- 肥胖与IL6表达增加、免疫细胞浸润和脂肪酸代谢特征相关。
核心结论
- 肥胖与单用来曲唑时较低的ORR相关,而在taselisib治疗患者中未观察到该关联。
研究设计与样本
- LORELEI(NCT02273973)是一项随机试验,评估新辅助PI3K抑制剂taselisib联合来曲唑对比安慰剂联合来曲唑在雌激素受体阳性/HER2阴性早期乳腺癌患者中的疗效。
- 共纳入329例患者,按BMI分类:正常体重(18.5-24.9 kg/m²)98例(29.8%),超重(25-29.9 kg/m²)125例(38%),肥胖(≥30 kg/m²)106例(32.2%)。
主要发现
- 在安慰剂组中,较高BMI与较低ORR相关(OR 0.90, 95%CI 0.83-0.97);在taselisib组中无关联(OR 1.03, 95%CI 0.96-1.11);交互作用P=0.007(未校正),P=0.013(校正后)。
- 肥胖患者中高血糖发生率为15.1%,腹泻发生率为24.5%。
- 在安慰剂组肥胖患者中,PI3K通路下游效应分子pS6水平较高与ORR增加相关(交互作用P=0.011)。
- 肥胖患者基线乳腺密度较低(P<0.001),但与ORR无关。
- 肥胖与IL6表达增加、免疫细胞浸润和脂肪酸代谢特征相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phosphoinositide 3-kinase (PI3K) pathway, involved in obesity-related signalling, may influence efficacy and toxicity of PI3K inhibitors (PI3Ki). We explored associations between body mass index (BMI) and objective response rate (ORR), safety, molecular features, and breast density in the LORELEI trial. METHODS: LORELEI (NCT02273973) was a randomized trial evaluating neoadjuvant PI3Ki taselisib plus letrozole vs placebo plus letrozole in patients with estrogen receptor-positive/HER2-negative early breast cancer. Patients were classified as normal weight (BMI 18.5-24.9 kg/m²), overweight (25-29.9 kg/m²), or obese (≥30 kg/m²). Logistic regression tested BMI by treatment arm, adverse events were analysed descriptively by BMI category. Immune composition and gene expression profiles were evaluated by RNA sequencing. RESULTS: Of 329 patients, 98 (29.8%) were classified as normal weight, 125 (38%) as overweight, and 106 (32.2%) as obese. In the placebo arm, higher BMI was associated with lower ORR [odds ratio (OR) 0.90, 95% CI 0.83-0.97]; no association was observed in the taselisib arm [OR 1.03, 95% CI 0.96-1.11; interaction p = 0.007 (unadjusted), p = 0.013 (adjusted)]. In patients with obesity the incidence of hyperglycaemia and diarrhoea was 15.1% and 24.5%, respectively. Higher levels of pS6, a downstream effector of the PI3K pathway, were associated with increased ORR in patients with obesity in the placebo arm (interaction p = 0.011). Patients with obesity had lower baseline breast density (p < 0.001), not associated with ORR. Obesity was associated with increased IL6 expression, immune cell infiltration, and fatty acid metabolism signature. CONCLUSIONS: Obesity was associated with lower ORR with letrozole alone, whereas this association was not observed in patients treated with taselisib.
引用
- Dauccia C, Franzoi MA, Saura C, et al. Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial. Eur J Cancer. 2026. PMID: 42308863. doi:10.1016/j.ejca.2026.116880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。